Compare AU
Compare DRUG vs. EDOC
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the BetaShares Digital Health and Telemedicine ETF (EDOC). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | EDOC | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 10 |
Median incremental investment | $967.00 | $705.01 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,905.75 | $624.97 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | EDOC | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | EDOC.AX was created on 2022-03-30 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. The investment objective of the BetaShares Digital Health and Telemedicine ETF is to provide an investment return that aims to track the performance of the NASDAQ CTA Global Digital Health Index (the Index), before taking into account fees and expenses. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | INSULET CORP (8.47 %) BOSTON SCIENTIFIC CORP (8.24 %) ABBOTT LABORATORIES (7.76 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Health Care (75.06 %) Other (24.70 %) Consumer Staples (14.33 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (77.51 %) China (13.32 %) Japan (4.67 %) |
Management fee | 0.57 % | 0.67 % |
Key Summary
DRUG | EDOC | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Nasdaq CTA Global Digital Health Index - AUD - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.67 % |
Price | $8.25 | $10.33 |
Size | $182.401 million | $1.525 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | - % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 29/03/2022 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | EDOC | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 10 |
Median incremental investment | $967.00 | $705.01 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,905.75 | $624.97 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | EDOC | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | EDOC |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |